Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Inhibition of microRNA function by antimiR oligonucleotides.

Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S.

Silence. 2012 Jan 9;3(1):1. doi: 10.1186/1758-907X-3-1.

2.

The therapeutic potential of microRNAs in cancer.

Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S.

Cancer J. 2012 May-Jun;18(3):275-84. doi: 10.1097/PPO.0b013e318258b5d6.

PMID:
22647365
3.

LNA-mediated microRNA silencing in non-human primates.

Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, Gullans S, Kearney P, Sarnow P, Straarup EM, Kauppinen S.

Nature. 2008 Apr 17;452(7189):896-9. doi: 10.1038/nature06783. Epub 2008 Mar 26.

PMID:
18368051
4.

Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease.

Kaucsár T, Rácz Z, Hamar P.

Adv Drug Deliv Rev. 2010 Nov 30;62(14):1390-401. doi: 10.1016/j.addr.2010.10.003. Epub 2010 Oct 19. Review.

PMID:
20940025
5.

MicroRNAs as targets for antisense-based therapeutics.

Stenvang J, Kauppinen S.

Expert Opin Biol Ther. 2008 Jan;8(1):59-81. Review.

PMID:
18081537
6.

Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.

Bernardo BC, Gao XM, Winbanks CE, Boey EJ, Tham YK, Kiriazis H, Gregorevic P, Obad S, Kauppinen S, Du XJ, Lin RC, McMullen JR.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17615-20. doi: 10.1073/pnas.1206432109. Epub 2012 Oct 9.

7.

MicroRNAs in cancer management and their modulation by dietary agents.

Karius T, Schnekenburger M, Dicato M, Diederich M.

Biochem Pharmacol. 2012 Jun 15;83(12):1591-601. doi: 10.1016/j.bcp.2012.02.004. Epub 2012 Feb 9. Review.

PMID:
22342289
8.

Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?

Weiler J, Hunziker J, Hall J.

Gene Ther. 2006 Mar;13(6):496-502. Review.

PMID:
16195701
9.

Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Cheng CJ, Saltzman WM, Slack FJ.

Curr Med Chem. 2013;20(29):3582-93. Review.

10.

Inter- and intra-combinatorial regulation by transcription factors and microRNAs.

Zhou Y, Ferguson J, Chang JT, Kluger Y.

BMC Genomics. 2007 Oct 30;8:396.

11.

MicroRNAs and their diverse functions in plants.

Sun G.

Plant Mol Biol. 2012 Sep;80(1):17-36. doi: 10.1007/s11103-011-9817-6. Epub 2011 Aug 27. Review.

PMID:
21874378
12.

microRNA target predictions in animals.

Rajewsky N.

Nat Genet. 2006 Jun;38 Suppl:S8-13. Review.

PMID:
16736023
13.

MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

van Rooij E, Olson EN.

Nat Rev Drug Discov. 2012 Nov;11(11):860-72. doi: 10.1038/nrd3864. Epub 2012 Oct 19. Review.

PMID:
23080337
14.

Strategies to identify microRNA targets: new advances.

Jin H, Tuo W, Lian H, Liu Q, Zhu XQ, Gao H.

N Biotechnol. 2010 Dec 31;27(6):734-8. doi: 10.1016/j.nbt.2010.09.006. Epub 2010 Oct 1. Review.

PMID:
20888440
15.

MicroRNAs: novel regulators in cardiac development and disease.

Thum T, Catalucci D, Bauersachs J.

Cardiovasc Res. 2008 Sep 1;79(4):562-70. doi: 10.1093/cvr/cvn137. Epub 2008 May 29. Review.

16.

Targeting of microRNAs for therapeutics.

Stenvang J, Lindow M, Kauppinen S.

Biochem Soc Trans. 2008 Dec;36(Pt 6):1197-200. doi: 10.1042/BST0361197.

PMID:
19021524
17.

LNA-modified oligonucleotides mediate specific inhibition of microRNA function.

Ørom UA, Kauppinen S, Lund AH.

Gene. 2006 May 10;372:137-41. Epub 2006 Feb 24.

PMID:
16503100
18.

MicroRNA silencing in primates: towards development of novel therapeutics.

Petri A, Lindow M, Kauppinen S.

Cancer Res. 2009 Jan 15;69(2):393-5. doi: 10.1158/0008-5472.CAN-08-2749. Review.

19.

Exploiting the therapeutic potential of microRNAs in viral diseases: expectations and limitations.

Hemida MG, Ye X, Thair S, Yang D.

Mol Diagn Ther. 2010 Oct 1;14(5):271-82. doi: 10.2165/11539540-000000000-00000. Review.

PMID:
21053993
20.

Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR.

Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, Sinha S, Goody RJ, Lawrence MS, deLemos AS, Hansen HF, Whittaker S, Henry S, Brookes R, Najafi-Shoushtari SH, Chung RT, Whetstine JR, Gerszten RE, Kauppinen S, Näär AM.

Sci Transl Med. 2013 Nov 20;5(212):212ra162. doi: 10.1126/scitranslmed.3006840.

Items per page

Supplemental Content

Write to the Help Desk